ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1298

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Outcome Improvement for Children with Juvenile Idiopathic Arthritis

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1320

Performance of FRAX® Brazil and NOGG Methodology with and Without Bone Mineral Density upon Predicting Fractures on a Community-Dwelling Elderly Population with High Incidence of Osteoporotic Fractures: The São Paulo Ageing and Health (SPAH) Study

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1432

Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1421

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of a Proposed Tocilizumab Biosimilar (MSB11456) versus US‑licensed Tocilizumab: Results of a Randomized, Double-blind, Parallel‑group, Single‑intravenous Dose Study in Healthy Adults (APTURA II)

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1250

Physiologic Adaptive Change of the Patellar and Achilles Tendons: Sensitivity to Change Detected by Computer Analysis of Sequential Static Images

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1303

Planning Transition in Times of Transition: Is There a Virtual Pathway from Pediatric to Adult Care?

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1275

Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1347

Poor Health-Related Quality of Life in Patients with Lupus Nephritis

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1282

Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1436

Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis

RA – Treatment Poster III

1:00PM-3:00PM: Abstract Number: 1411

Predictors of Achieving Clinical Remission in ACPA-positive RA-patients Treated with Abatacept and Methotrexate or Methotrexate Monotherapy

RA – Diagnosis, Manifestations, and Outcomes Poster III

1:00PM-3:00PM: Abstract Number: 1453

Prevalence and Associations of Myositis in an Indian Inception Cohort of Lupus

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1218

Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry

Fibromyalgia and Other Clinical Pain Syndromes Poster

1:00PM-3:00PM: Abstract Number: 1477

Prevalence and Risk Factors of Fragility Fractures in Systemic Lupus Erythematosus: A Longitudinal Study over 12 Years

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1308

Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].